Research advance of population pharmacokinetics of imipenem-cilastatin in special status populations
- VernacularTitle:特殊状态人群中亚胺培南-西司他丁的群体药动学研究进展
- Author:
Jianli ZUO
1
;
Yao HE
1
;
Fushu LI
1
;
Xing CHEN
1
;
Xiaoyuan ZHENG
1
Author Information
1. Dept. of Pharmacy，Chongqing Emergency Medical Center/Chongqing University Central Hospital，Chongqing 400014，China
- Publication Type:Journal Article
- Keywords:
Imipenem-cilastatin;
population pharmacokinetics;
continuous renal replacement therapy;
extracorporeal membrane
- From:
China Pharmacy
2022;33(9):1141-1146
- CountryChina
- Language:Chinese
-
Abstract:
Imipenem-cilastatin is a broad-spectrum carbapenem antibiotic drug that has been widely used in clinical practice ， but there is a lack of guidelines and expert consensus on the development of individualized regimens for special status populations [e.g. continuous renal replacement therapy （CRRT）patients，extracorporeal membrane oxygenation （ECMO）patients， critically ill burn patients ，neonates and children]. In this paper ，by searching population pharmacokinetics research of imipenem- cilastatin in special status populations ，it is recommended that imipenem-cilastatin is given 1 to 3 g/d for CRRT patients ；500 mg to 1 g，q6 h for burn patients ；750 mg to 1 g，q6 h for ECMO patients ；20 mg/kg or 25 mg/kg，q8 h for neonates ；and 25 mg/kg，q6 h for children.
